Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Abivax SA ( (FR:ABVX) ) has provided an announcement.
Abivax released information regarding its share capital and voting rights, indicating a total of 63,347,837 shares and 70,991,046 exercisable voting rights as of December 31, 2024. This disclosure is part of regulatory requirements and provides transparency for stakeholders, potentially impacting investor confidence and market activities related to Abivax’s shares.
More about Abivax SA
Abivax is a clinical-stage biotechnology company focused on developing therapeutic solutions to stabilize the immune response in patients with chronic inflammatory diseases. The company operates in France and the United States, with its leading drug candidate, obefazimod (ABX464), undergoing phase 3 clinical trials for ulcerative colitis.
YTD Price Performance: -11.23%
Average Trading Volume: 818
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €386.5M
For detailed information about ABVX stock, go to TipRanks’ Stock Analysis page.
